LAS VEGAS, Jan. 7, 2008 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (OTCBB:SPHC), a biopharmaceutical company focused on developing innovative therapeutics in the areas of CNS, cancer, cardiovascular, and infectious diseases, has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan’s commitment to maintain a majority of independent members that reflects today’s best practices on its Board. Samaritan’s board is now comprised of eight independent directors and two internal directors.
